Ipragliflozin

Ipragliflozin
Clinical data
Trade names	Suglat
Identifiers
	IUPAC name (1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol;
PubChem CID	10453870;
ChemSpider	8629286;
KEGG	D10196;
ChEMBL	ChEMBL2018096;
CompTox Dashboard (EPA)	DTXSID701032738 ;
Chemical and physical data
Formula	C21H21FO5S
Molar mass	404.45 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES S1C(=CC2=C1C=CC=C2)CC=2C=C(C=CC2F)[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO;
	InChI InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1 COPY; Key:AHFWIQIYAXSLBA-RQXATKFSSA-N;

Ipragliflozin (Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. It was approved for use in Japan in 2014.^[1]

Ipragliflozin is an SGLT2 inhibitor.^[2]

References

^ "Ipragliflozin (Suglat) First of New Diabetes Drug Class in Japan". Medscape. January 20, 2014.
^ Takasu T, Takakura S, Kaku S (2015). "Pharmacological and clinical profile of ipragliflozin (Suglat(®)): a new therapeutic agent for type 2 diabetes". Nihon Yakurigaku Zasshi. 145 (1): 36–42. doi:10.1254/fpj.145.36. PMID 25743234.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.